Page History
Definition
An abstract : A representation of a medicinal product as it is supplied in a package for placement into the supply chain, based on description of and quantity of the clinical drug(s) contained within that package.
As an abstract class, the Packaged Clinical Drug is placed on the left hand lefthand side of the overall model, relating directly to the Clinical Drug class in the international core by means of a composition relationship, but its population is the responsibility of national extensions since the amount of content needed to support this internationally would be overwhelming and unmanageable in maintenance and verification.
This definition supports the description of kit or combination products (- medicinal products that are composed of more than one Clinical Drug - clinical drug, such as a package containing fluconazole oral capsules and clotrimazole cream for treatment of vaginal thrush ) as Packaged Clinical Drugsas packaged clinical drugs, and therefore the pack size information for each Clinical Drug clinical drug that is a component in the package is grouped together. Further detail on the description of combination products (multi-component or kit products) is given in Section 11 below.below.
Use Cases
The following use cases are supported by the Packaged Clinical Drug concept class:
- Reimbursement: national or local systems may set pricing or eligibility against an abstract representation of real packaged products (e.g., for interchangeability and substitution)
- As a linking class from the international core to the Real Packaged Clinical Drug class for any national extension that did not require a Real Clinical Drug class (i.e., if all products are authorised in their packaged form)
- To support description of combination packaged products
Discussion
Packs of medicinal products must be represented using the closed world view; they contain only the clinical drug content stated. The packaged clinical drug class is related to the clinical drug class by a composition relationship, the package contains the clinical drug. To correctly describe that this and so to ensure that pack concepts classify correctly, and so that packs that contain more than one (type of) clinical drug (i.e., combination packs) do not classify as children of packs that contain only one type of clinical drug, it is necessary to use a "clinical drug count" attribute as a proxy for the closed world view. This mirrors , in a similar way to the use of the active ingredient count attribute used for active ingredient in the MP only concepts, MPF only concepts, and CD concepts in the main medicinal product hierarchy. By clinical drug concepts. By using a "count" attribute in the definition of Clinical Drug and Package concepts, when concreted domains are implemented in the SNOMED CT overall concept modelclosed world concepts, the count information will be is machine processable; similarly , and therefore, if/when a more expressive description logic becomes available to properly represent the closed world view, then all the count attributes can be removed consistently.used to transfer to the closed world description logic consistently.
| Gliffy Diagram | ||||||||
|---|---|---|---|---|---|---|---|---|
|
Figure 32: Diagram of the packaged clinical drug class and its composition relationship to clinical drug, with an example (Zocor)
The national extension model does not represent intermediate layers of packaging; it represents only the outer package used in the supply chain. Describing "sub-packs " (e.g., tablets within blister sleeves, which are then within a container such as a box) is complex for a description logic based model and is currently out of scope for this initial version of the national extension specification. In most nations, sub-packs are re are primarily used for supply chain management and reimbursement purposes, and possibly rounding of dispense amounts so that sub-packs are not split. Many medicinal product terminologies do not represent sub-packs. ISO 11615, the Medicinal Product part of the IDMP suite of standards, has a full sub-pack mode, but the sub-packs themselves are not identified concepts and so are not available for mapping, etc.; however the GS1 , the GS1 implementation of ISO TS 16791 does include identification of sub packs. The basic model described here does not deal with sub-packs; a concept model for sub-packs will not be undertaken until there are requests with confirmed clinical use cases. See also Appendix 2.
Figure 16: Diagram the Packaged Clinical Drug class and its composition relationship to Clinical Drug, with an example
.
Existing national terminology equivalents:
- UK's NHS dm+d this is the Virtual Medicinal Product Pack (VMPP) class
- The AMT/NZULM it is the Medicinal Product Pack
- In Ireland, this is in effect those packaged products on the Representative Pricing list
- The generic pack (GPCK) class in RxNorm
Attributes
...
The following is described for Packaged Clinical Drugs table describes the attributes for packaged clinical drugs that contain one Clinical Drug only, that type of clinical drug only. That is they are NOT combination (multi-component or kit) products. See Section 11 below for Combination Products.
The packaged clinical drug The Packaged Clinical Drug class is related to the Clinical Drug clinical drug class by a composition relationship relationship, and therefore the attribute "contains clinical drug" , the
| Concept | ||
|---|---|---|
|
Representation of packaged medicinal products should use Clinical Drugs clinical drugs that have presentation strength (either only, or in addition to, concentration strength) whenever possible in order to be able to accurately describe the number of presentation units present in the package. The exception will be is for continuous products such as semi-solid dose forms of creams, gels, etc. where strength pattern 3a is used (see international Editorial Guidelines International Medicinal Product Model). In all cases the pack size and pack size unit should relate to the denominator unit of the strength.
| Semantic tag | (packaged clinical drug) | |||
|---|---|---|---|---|
| Definition status |
| |||
Attribute: | |
|---|---|
Contains clinical drug
- Range: 763158003 |Medicinal product (product)| - descendants only (see Note 1 below)
- Cardinality: 1..1
The attribute value should represent the clinical drug that is contained in the packaged product
Attribute:
Count of clinical drug type
| Range
Cardinality | |||
|---|---|---|---|---|
Note
|
|
|
Attribute:
Has pack size
- Range: 260299005|Number (qualifier value) - descendants only
- Cardinality: 1..1 (per relationship group)
The attribute value should represent the amount or quantity of clinical drug present in the package (see 10.3 below)
Attribute:
Has pack size unit
- Range: 258666001|Unit (qualifier value) - descendants only
- Cardinality: 1..1 (per relationship group)
The attribute value should represent the units for the amount or quantity of clinical drug present in the package (see 10.3 below)
...
| ||||||
Role Group (although for all packages other than combination products it is 1..1) | Attribute:
| Range
Cardinality
Note
|
|---|
...
|
...
|
...
|
...
|
...
| |
Attribute:
|
...
| Range
Cardinality
Note
| ||||
Attribute:
| Range
Cardinality
Note
|
...
|
...
|
...
|
...
|
...
|
...
|
Example Diagrams
Some examples of packaged clinical drug (PCD) . Therefore, the Has_pack_size_unit should be explicitly valued.
...
concepts are shown below.
Stated template view:
Gliffy Diagram size 800 name PCD template pagePin 1
Figure 1733: Template for Packaged Clinical Drug
Example (stated view):
simple packaged clinical drug
Example: single active ingredient substance presentation strength packaged clinical drug: stated view followed by the inferred view
Figure 34Figure 18: Example of a presentation strength packaged clinical drug - stated view
Example (inferred view):
Figure 35: Example of a presentation strength packaged clinical drug - inferred view
Example: single active ingredient substance presentation strength packaged clinical drug: stated view followed by the inferred view
Figure 36: Example of a concentration strength packaged clinical drug - stated view
Figure 37Figure 19: Example of a concentration packaged clinical drug - inferred view
Optional
...
Additional Information
The following information may be additionally used to describe the Packaged Clinical Drug characteristics of the packaged clinical drug concept in a national extension. The attribute concepts and values to populate these if this data is to be held in a structured form, may be available in the international release in the future, particularly for those concepts such as package/container types that have international applicability and which can be sourced and maintained reliably.:
- Package/container type (e.g., bottle, box, jar, tube) - see 10.6
- Administration device supplied in the package (e.g., medicine spoon, vaginal applicator, applicator brush for cutaneous liquid products)
Use cases supported by Packaged Clinical Drug
The following use cases are supported by the Packaged Clinical Drug concept class:
- Reimbursement: national or local systems may set pricing or eligibility against an abstract representation of real packaged products (e.g. for interchangeability and substitution)
- As a linking class from the international core to the Packaged Product class for any national extension that did not require a Real Clinical Drug class (i.e. if all products are authorised in their packaged form)
- To support description of combination packaged products, if the quantity of each component in the combination packaged product is required
...
IDMP Compatibility
There is no representation of a class similar to the Packaged Clinical Drug concept class; the primary use case for this class beyond support for generic representation of combination products is reimbursement, which is out of scope of IDMP. Combination products in their entirety are only represented in IDMP in their authorised form; there is no PhP type representation for them.
Overview
Content Tools
Apps